Rain Oncology Inc. (RAIN)
收市後：
| 前收市價 | 0.8618 |
| 開市 | 0.8410 |
| 買盤 | 0.8410 x 800 |
| 賣出價 | 0.9078 x 1100 |
| 今日波幅 | 0.8410 - 0.8650 |
| 52 週波幅 | 0.8220 - 14.4800 |
| 成交量 | |
| 平均成交量 | 266,946 |
| 市值 | 31.261M |
| Beta 值 (5 年，每月) | 0.21 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.5700 |
| 業績公佈日 | 2023年11月08日 - 2023年11月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 4.55 |
Insider MonkeyRain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […]
BenzingaRain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity
Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO. Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten
